<DOC>
	<DOC>NCT01890538</DOC>
	<brief_summary>This study aims to investigate efficacy of two different intravenous drugs (dimenhydrinate and piracetam) in the symptomatic management of peripheral vertigo. The patients will be randomized in two groups according to symptomatic treatment modalities: Dimenhydrinate (100 mg) and piracetam (2 g) will be given in 100 cc normal saline in 30 minutes. Each patient will be asked if her/his vertigo symptoms resolved or not, according to a numeric rating scale (0=no vertigo, 10=worst possible vertigo). The patient will be rate the intensity of symptoms in the following times: - Numeric rating scale (1 to 10): Admission - Numeric rating scale (1 to 10): After the study drug (No ambulation)* - Numeric rating scale (1 to 10): After the study drug (Ambulation)* - Ambulation refers to head movements or walking in the room, if applicable.</brief_summary>
	<brief_title>Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo</brief_title>
	<detailed_description />
	<mesh_term>Vertigo</mesh_term>
	<mesh_term>Dizziness</mesh_term>
	<mesh_term>Dimenhydrinate</mesh_term>
	<criteria>Presenting to emergency department with vertigo symptoms Adult patients (over 18) Agree to participate to study (understanding the study protocol and signing the informed consent form) Patients under 18 years Patients diagnosed with ischemic/hemorrhagic stroke after neuroimaging Patient diagnosed with transient ischemic attack Pregnants Patients taking any analgesics or antihistaminic drugs last 24 hours Documented or declared allergy to dimenhydrinate, piracetam or benzodiazepines Patients who do not agree to participate to the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>vertigo</keyword>
	<keyword>dimenhydrinate</keyword>
	<keyword>piracetam</keyword>
</DOC>